Patent landscape
Rybrevant (amivantamab-vmjw)
Janssen Biotech, Inc. · Targets: EGFR, MET · First FDA approval 2021-05-21
Purple Book + BigQuery
Patent data as of 2026-05-15
Curated patents
96
96 families
Global footprint
2,748
across 62 countries
Multiplier
29×
intl docs / curated patents
Cliff closes
Nov 3, 2041
Last US lifecycle patent falls
Cliff opens
Aug 7, 2020
Foundational composition expiry
Cliff window: opened Aug 7, 2020 (foundational composition expired) and closes Nov 3, 2041 (last US lifecycle patent falls). Biosimilar entry typically lands mid-window via negotiated settlement — Humira biosimilars entered ~7 years past composition expiry under licensing agreements with AbbVie.
International footprint: Curated thicket data identifies 96 US patents.
BigQuery family expansion shows the same inventions filed as 2,748 documents across 62 countries in 96 patent families — 29× the US count.
Patent portfolio
Family-by-family interpretation: which family anchors composition, which add lifecycle, when each expires.
TheraRadar's curated thicket identifies 96 patents across 96 families for amivantamab-vmjw, comprising 2,748 international documents across 62 countries. This represents a notable 28.6x multiplier of international documents to curated patents, reflecting a broad global filing strategy for this biologic, though these are curated patents and not FDA-listed.
Pro Composition anchor, lifecycle layers, outlook — Remaining 4 sections of the estate analysis
See what Pro includes ↓ Orange Book patent stack
96 unique patents listed against this drug. All mapped to BigQuery patent families.
| Patent | Family | Claim type | Use code | US expiry |
|---|---|---|---|---|
| US 8329171 | 27397221 | — | — | August 7, 2020 |
| US 9828424 | 40454732 | — | — | August 7, 2020 |
| US 8894990 | 36602254 | — | — | August 7, 2020 |
| US 7595378 | 32680703 | — | — | June 13, 2021 |
| US 7247301 | 23149369 | — | — | June 13, 2021 |
| US 7597892 | 32930206 | — | — | August 23, 2021 |
| US 9939452 | 32039081 | — | — | September 27, 2022 |
| US 8603469 | 32681965 | — | — | December 16, 2022 |
| US 11180549 | 37308556 | — | — | April 29, 2025 |
| US 7825223 | 37433887 | — | — | June 17, 2025 |
| US 11185584 | 37605195 | — | — | June 30, 2025 |
| US 10155816 | 37781799 | — | — | November 28, 2025 |
| US 9353181 | 38218878 | — | — | December 29, 2025 |
| US 7918125 | 39344997 | — | — | October 31, 2026 |
| US 9212230 | 39672666 | — | — | March 29, 2027 |
| US 9540450 | 40224463 | — | — | September 6, 2027 |
| US 8748356 | 40304294 | — | — | October 19, 2027 |
| US 8898047 | 39530171 | — | — | February 29, 2028 |
| US 9285361 | 41505499 | — | — | July 3, 2028 |
| US 9238693 | 42129569 | — | — | October 31, 2028 |
| US 9150658 | 59050110 | — | — | December 9, 2028 |
| US 8163500 | 40568393 | — | — | December 12, 2028 |
| US 9988437 | 44588173 | — | — | August 13, 2029 |
| US 8580714 | 43876863 | — | — | October 14, 2029 |
| US 9657107 | 44342987 | — | — | March 10, 2030 |
| US 10597464 | 44226045 | — | — | April 20, 2030 |
| US 10941197 | 45934343 | — | — | October 13, 2030 |
| US 11578141 | 47041975 | — | — | April 20, 2031 |
| US 9102737 | 49157853 | — | — | March 15, 2032 |
| US 9611327 | 46514282 | — | — | July 9, 2032 |
| US 12247077 | 59896349 | — | — | November 21, 2032 |
| US 9593164 | 50728148 | — | — | November 21, 2032 |
| US 11191668 | 51530838 | — | — | March 14, 2033 |
| US 11014987 | 60242456 | — | — | December 24, 2033 |
| US 10864268 | 54705894 | — | — | November 18, 2034 |
| US 10865253 | 55069840 | — | — | December 19, 2034 |
| US 10544220 | 56355550 | — | — | January 8, 2035 |
| US 10457735 | 55072677 | — | — | January 8, 2035 |
| US 10844122 | 57218080 | — | — | May 6, 2035 |
| US 10195316 | 57545759 | — | — | June 17, 2035 |
| US 12595316 | 56296828 | — | — | July 9, 2035 |
| US 10669343 | 57944010 | — | — | August 5, 2035 |
| US 10544229 | 58409279 | — | — | September 30, 2035 |
| US 12247080 | 58796495 | — | — | December 1, 2035 |
| US 10465003 | 59500155 | — | — | February 5, 2036 |
| US 10899836 | 58159110 | — | — | February 12, 2036 |
| US 11214600 | 59563610 | — | — | February 12, 2036 |
| US 10730950 | 59789819 | — | — | March 8, 2036 |
| US 11197913 | 58609978 | — | — | March 29, 2036 |
| US 11104724 | 60412636 | — | — | May 23, 2036 |
| US 11091557 | 59501399 | — | — | July 14, 2036 |
| US 11884722 | 60992891 | — | — | July 20, 2036 |
| US 11359029 | 61158615 | — | — | August 12, 2036 |
| US 11673943 | 60473574 | — | — | November 3, 2036 |
| US 11208474 | 62106652 | — | — | November 16, 2036 |
| US 12122824 | 62977170 | — | — | January 30, 2037 |
| US 11014982 | 63039142 | — | — | February 7, 2037 |
| US 11357907 | 63105962 | — | — | February 10, 2037 |
| US 11512137 | 62044657 | — | — | March 31, 2037 |
| US 11192951 | 64566522 | — | — | June 5, 2037 |
| US 11149094 | 64458754 | — | — | June 5, 2037 |
| US 11746161 | 64562613 | — | — | June 5, 2037 |
| US 12091452 | 65808646 | — | — | September 25, 2037 |
| US 12404324 | 66326843 | — | — | November 6, 2037 |
| US 12398209 | 65529735 | — | — | January 22, 2038 |
| US 12138295 | 67767864 | — | — | March 5, 2038 |
| US 12246025 | 67986634 | — | — | March 21, 2038 |
| US 11154421 | 66655396 | — | — | April 20, 2038 |
| US 12234283 | 66429636 | — | — | April 20, 2038 |
| US 12324841 | 68467057 | — | — | May 7, 2038 |
| US 11578124 | 68532802 | — | — | May 18, 2038 |
| US 11466082 | 67211770 | — | — | May 24, 2038 |
| US 12275797 | 67139695 | — | — | June 22, 2038 |
| US 12247065 | 62841830 | — | — | June 22, 2038 |
| US 10961307 | 69885324 | — | — | September 24, 2038 |
| US 12453781 | 68582459 | — | — | October 30, 2038 |
| US 11634499 | 70551717 | — | — | November 13, 2038 |
| US 11548941 | 70727469 | — | — | November 20, 2038 |
| US 12415859 | 71073358 | — | — | December 18, 2038 |
| US 12215161 | 72142314 | — | — | February 26, 2039 |
| US 12264197 | 71670296 | — | — | March 11, 2039 |
| US 12180271 | 69784489 | — | — | March 14, 2039 |
| US 12122825 | 69784490 | — | — | March 14, 2039 |
| US 12202892 | 72662887 | — | — | April 4, 2039 |
| US 11591395 | 70465163 | — | — | April 19, 2039 |
| US 12448455 | 73289471 | — | — | May 14, 2039 |
| US 11780911 | 73457645 | — | — | May 23, 2039 |
| US 12435154 | 75870647 | — | — | May 8, 2040 |
| US 12258393 | 78608637 | — | — | May 21, 2040 |
| US 11535679 | 77914293 | — | — | September 10, 2040 |
| US 11548952 | 77914294 | — | — | September 10, 2040 |
| US 11608383 | 77914292 | — | — | September 10, 2040 |
| US 11858995 | 77924347 | — | — | September 10, 2040 |
| US 11845805 | 77924348 | — | — | September 10, 2040 |
| US 12534524 | 82701639 | — | — | July 9, 2041 |
| US 12098210 | 86242021 | — | — | November 3, 2041 |
Patent families — global footprint
Family-deduplicated portfolio across all jurisdictions. Each family represents a single invention with related filings in multiple countries.
Pro Patent families — global footprint — Country-by-country lists, family-level priority dates, continuation patterns across all jurisdictions
See what Pro includes ↓ International vs US — composition family
Most jurisdictions follow priority + 20 years. US adds Patent Term Adjustment (PTA); EU adds Supplementary Protection Certificate (SPC); Japan adds Patent Term Extension (PTE). Latest US Orange Book expiry includes these extensions.
Priority date
2000-08-07
Family 27397221
Nominal global expiry
2020-08-07
priority + 20 years
Latest US OB expiry
includes US PTA
Coverage status
What this page covers, what's coming in a future refresh, and what's out of scope.
| Category | What's covered | Status | |
|---|---|---|---|
| ⚠ | Curated patent seeds (not FDA-listed) | 96 patents identified via Google Patents BigQuery search of Merck/MSD-assigned anti-PD-1 patents. Biologics aren't FDA-listed in Orange Book, and Purple Book doesn't mandate patent disclosure — so this thicket is curated, not authoritative. | Curated |
| Curated from Google Patents (BigQuery, 3-assignee search + drug-name/code keywords, granted patents only). Not FDA-authoritative; may miss manufacturing patents, pending applications, or patents under un-filtered assignees. | |||
| ✓ | Same-family international | 2,748 documents across 62 countries via BigQuery family expansion | Complete |
| ✓ | Nominal international expiry | Priority date + 20 years computed per family. Composition family nominal expiry: 2020-08-07. | Complete |
| ✓ | Estate analysis | LLM-generated structural analysis, constrained to patent data only — no commercial, financial, or litigation claims included | Complete |
| ○ | Country-specific extensions | EU SPC, JP PTE, KR PTE not modeled. US Orange Book expiry already includes US PTA. Most ex-US jurisdictions follow priority + 20 years (shown). | Known limitation |
| ✕ | Hatch-Waxman / BPCIA settlement terms | Specific settlement terms (royalty %, launch dates) are confidential between parties | Out of scope |
| ✕ | Commercial / M&A history | Deal terms, royalty stacks, contingent value rights — not in patent data | Out of scope |
Frequently asked
Common questions about Rybrevant's patent landscape
- When will biosimilars enter the market for Rybrevant?
- Rybrevant's foundational composition patent already expired (Aug 7, 2020), so the cliff window is open. The cliff closes Nov 3, 2041 when the last US lifecycle patent falls. Whether biosimilars have actually entered depends on the strength of secondary patents (formulations, methods of use, manufacturing) and whether settlements were reached — the Humira precedent saw biosimilars enter ~7 years past composition expiry under licensing agreements with AbbVie.
- What's the difference between "cliff opens" and "cliff closes"?
- Cliff opens (Aug 7, 2020) marks Rybrevant's foundational composition patent expiry — the earliest theoretical date for biosimilar entry. Cliff closes (Nov 3, 2041) is when the last US patent in the thicket finally falls — after which the market has no patent-based barriers. The gap between these two dates is the lifecycle-extension window: secondary patents (formulations, methods of use, manufacturing) that can block biosimilars even after the composition patent has expired.
- Why is Rybrevant in the Purple Book?
- Rybrevant is regulated via the FDA biologic license application (BLA) pathway and listed in the FDA Purple Book (biologics). Biologics are not required to list patents with the FDA — the Purple Book does not include patent listings. The patents shown here are curated by TheraRadar via Google Patents BigQuery search of the sponsor (Janssen Biotech, Inc.) and mechanism keywords, not pulled from an FDA list.
- What's a patent family and why does it matter?
- A patent family is a group of patent applications and grants worldwide that share the same priority filing (the earliest invention disclosure). One US patent often expands to 20–40+ filings across different jurisdictions — each grant in a different country protecting the same underlying invention. Rybrevant has 96 families that resolve to 2,748 international documents across 62 countries. Families matter because biosimilar entry requires clearing patent barriers in each market separately — a US biosimilar launch is independent of EU or Japan launches.
- How were these Rybrevant patents identified?
- Rybrevant is a biologic, and the FDA's Purple Book does not include patent listings. TheraRadar identified these 96 patents via Google Patents BigQuery search using the sponsor (Janssen Biotech, Inc.) plus mechanism-specific keywords. This is a curated thicket, not an authoritative FDA list. We then expand each patent to its full international family using the BigQuery patent family graph. Coverage is best-effort and may not capture every patent the sponsor holds.
- What does the "Multiplier" stat mean?
- The multiplier shows how many international patent documents exist for every US patent in Rybrevant's thicket — calculated as 2,748 international documents ÷ 96 US patents = 29×. A high multiplier (>10×) indicates an aggressive global filing strategy — the sponsor has filed in many countries to maximize geographic protection. A low multiplier suggests the patent estate is US-centric, with limited international protection.
Methodology & data sources
- Orange Book patents: FDA Orange Book via TheraRadar's
fetch-orange-book.js, refreshed 2026-05-26. - Patent families & international docs: BigQuery
patents-public-data.patents.publications, queried 2026-05-15. Seed lookup → family expansion → priority date aggregation. - Nominal global expiry: earliest priority_date per family + 20 years. Does not include country-specific extensions (US PTA, EU SPC, JP PTE).
- Estate analysis: generated by gemini-3-pro-preview, constrained to structural patent data only. No commercial, financial, or litigation claims included.
Intelligence, not legal advice. Patent expiry shown is nominal where indicated; actual market timing depends on PTA/SPC/PTE, exclusivity overlays, pediatric extensions, IPR/PTAB outcomes, and Hatch-Waxman litigation. Consult patent counsel for precise jurisdiction-by-jurisdiction analysis.
TheraRadar Pro — patent intelligence
Free covers what's publicly listed: Orange Book patents, basic stats, composition expiry. Pro adds the deeper view: LLM-driven estate analysis, full international family thicket, and (coming soon) alerts + exports.
Always free
- • Orange Book patent table (every patent, family, use code, expiry)
- • Stat strip — OB count, families, global doc footprint, multiplier
- • Composition family priority + nominal global expiry
- • International vs US expiry comparison
- • Coverage status + methodology
- • Cross-link to mechanism / class landscape
PRO
What Pro adds today
- Estate analysis (sections 2-5) — Composition anchor, lifecycle layers, international vs US, strategic outlook
- Full patent families table — Country lists, doc counts, priority dates per family
- International nominal expiries — Priority + 20 years per family with global vs US gap
$99/year. Cancel anytime. Single sign-on via Google.
Patent data updated: May 26, 2026